Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers at National Cancer Institute target breast cancer
February 5th, 2009
According to recent research from the United States, "Novel genetic profiling tests of breast cancer tissue have been shown to be prognostic for overall survival and predictive of local and distant rates of recurrence in breast cancer patients. One of these tests, Oncotype DX (TM), is a diagnostic test comprised of a 21-gene assay applied to paraffin-em bedded breast cancer tissue, which allows physicians to predict subgroups of hormone-receptor-positive, node-negative patients who may benefit from hormonal therapy alone or require adjuvant chemotherapy to attain the best survival outcome." "The results of the assay are converted to a recurrence score (0-100) that has...
Source: Women's Health Weekly (2009-02-05)
|
